文献速递消化系统肿瘤

不可手术方式治疗技术上可切除胰腺癌的消融放疗

Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项队列研究纳入25例组织学确诊、影像学可切除的T1-2N0-1M0胰腺导管腺癌患者,因非肿瘤合并症不适合手术而接受消融放疗。2年总生存率43.7%,局部进展累积发生率20.8%,远处无转移生存率20.0%;3级急性及晚期胃肠道毒性分别见于3例和1例,无4级及以上事件。

要点

  • 消融放疗后2年总生存率43.7%(95%CI 27.4%-69.5%)。
  • 2年局部进展累积发生率20.8%(95%CI 7.3%-39.0%)。
  • 3级急性及晚期胃肠道毒性分别见于3例和1例,无4级及以上事件。

核心结论

  • 在技术上可切除的胰腺导管腺癌患者中,消融放疗实现了有效的局部肿瘤控制和较好的总生存,尽管该队列年龄较大、卡氏功能状态评分较差且化疗使用保守。
  • 这些数据支持对可切除胰腺导管腺癌开展消融放疗的前瞻性研究。

研究设计与样本

  • 这项队列研究从前瞻性维护的数据库中纳入2016年6月至2022年12月在纪念斯隆-凯特琳癌症中心接受消融放疗的连续患者,均为组织学确诊、影像学可切除的T1-2N0-1M0胰腺导管腺癌。
  • 患者因非肿瘤相关合并症不适合手术,共25例;数据于2023年12月冻结分析,分析于2024年3月至11月进行。
  • 所有患者接受的消融放疗生物有效剂量超过97.5 Gy,采用每日计算机断层扫描或磁共振成像引导、运动管理以及每日或选择性剂量分布自适应。

主要发现

  • 25例接受消融放疗的影像学可切除胰腺导管腺癌患者中,13例(52%)为男性,消融放疗时中位(IQR)年龄为80(74-87)岁。
  • 20例(80%)患者卡氏功能状态评分≤80,15例(60%)肿瘤为T2,4例(16%)淋巴结阳性。
  • 17例(68%)患者接受诱导化疗,中位(范围) duration 为2.9(1.0-6.1)个月。
  • 常规直线加速器放疗方案包括:13例接受75 Gy分25次,9例接受67.5 Gy分15次,2例接受50 Gy分5次(磁共振成像引导直线加速器),1例接受60 Gy分10次。
  • 2年总生存率为43.7%(95%CI 27.4%-69.5%),2年局部进展累积发生率为20.8%(95%CI 7.3%-39.0%),2年远处无转移生存率为20.0%(95%CI 9.1%-43.8%)。

临床怎么用

  • 作者认为,这些数据支持对可切除胰腺导管腺癌开展消融放疗的前瞻性研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Surgical resection of pancreatic ductal adenocarcinoma (PDAC) modestly improves long-term survival due to the competing risk of metastatic disease. However, postoperative morbidity often interferes with administration of systemic therapy and may be unacceptable to some patients. Ablative radiation therapy (A-RT) has emerged as an effective noninvasive local treatment in many tumor types and may provide an alternative to surgery in select patients with resectable PDAC. OBJECTIVE: To estimate the efficacy of A-RT in technically resectable PDAC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of consecutive patients with histologically confirmed, radiographically resectable T1-2N0-1M0 PDAC treated with A-RT at Memorial Sloan Kettering Cancer Center between June 2016 and December 2022 were included from a prospectively maintained database. Patients were not eligible for surgery because of noncancer-related comorbidities. Data were frozen for analysis in December 2023, which took place between March and November 2024. EXPOSURES: All patients received A-RT exceeding 97.5-Gy biologically effective dose with daily computed tomography or magnetic resonance imaging guidance, motion management, and daily or selective adaptation of the dose distribution. MAIN OUTCOMES AND MEASURES: The primary outcome was overall survival (OS). Secondary outcomes included biochemical and radiographic objective response rate, cumulative incidence of local progression, progression-free survival, and distant metastasis-free survival. RESULTS: Of 25 patients with radiographically resectable PDAC who received A-RT, 13 (52%) were male, and the median (IQR) age at time of A-RT was 80 (74-87) years. A total of 20 patients (80%) had a Karnofsky Performance Status score of 80 or lower. A total of 15 tumors (60%) were T2, and 4 (16%) were node positive. A total of 17 patients (68%) received induction chemotherapy for a median (range) of 2.9 (1.0-6.1) months. Radiation therapy regimens delivered with conventional linear accelerators included 75 Gy in 25 fractions among 13 patients, 67.5 Gy in 15 fractions among 9 patients, 50 Gy in 5 fractions among 2 patients (magnetic resonance imaging-guided linear accelerator), and 60 Gy in 10 for 1 patient. OS, local progression, and distant metastasis-free survival at 2 years were 43.7% (95% CI, 27.4%-69.5%), 20.8% (95% CI, 7.3%-39.0%), and 20.0% (95% CI, 9.1%-43.8%), respectively. Grade 3 acute and late gastrointestinal tract toxic effects were noted in 3 and 1 patients, respectively, with no grade 4 or higher events. CONCLUSIONS AND RELEVANCE: In this cohort study, A-RT in patients with technically resectable PDAC led to effective local tumor control and favorable OS despite advanced age, poor Karnofsky Performance Status score, and conservative use of chemotherapy in the cohort studied. These data support a prospective study of A-RT for the management of resectable PDAC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Reyngold M, Schoenfeld JD, O'Reilly EM, et al. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. JAMA Oncol. 2025. PMID: 40208620. doi:10.1001/jamaoncol.2025.0460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。